Anebulo Pharmaceuticals Inc (ANEB)
1.588
+0.07
(+4.50%)
USD |
NASDAQ |
Nov 15, 16:00
Anebulo Pharmaceuticals Research and Development Expense (TTM): 3.549M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.549M |
| March 31, 2024 | 4.498M |
| December 31, 2023 | 4.839M |
| September 30, 2023 | 5.647M |
| June 30, 2023 | 5.600M |
| March 31, 2023 | 5.301M |
| December 31, 2022 | 5.127M |
| Date | Value |
|---|---|
| September 30, 2022 | 3.470M |
| June 30, 2022 | 2.962M |
| March 31, 2022 | 3.650M |
| December 31, 2021 | 3.008M |
| September 30, 2021 | 2.965M |
| June 30, 2021 | 2.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.27M
Minimum
Jun 2021
5.647M
Maximum
Sep 2023
4.068M
Average
3.650M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Revance Therapeutics Inc | 77.24M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |